This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement. Eligible participants will receive 5 g oral HA35 once daily on an empty stomach for 40 consecutive days. The primary objectives are to assess changes in facial and body subcutaneous fullness, inflammatory erythema, facial vitality, and body weight. Safety, gastrointestinal tolerability, and additional exploratory outcomes will be evaluated throughout the intervention period. This is a minimal-risk, oral, non-pharmacological supportive care intervention.
Age 18-60 years, male or female
Seeking non-invasive improvement of facial/body appearance
Presenting with facial fullness, double chin, subcutaneous fat accumulation, facial erythema, or dull skin
Ability to complete VAS assessments and study logs
Aesthetic/weight loss treatments (injection, laser, liposuction, diet drugs) within 4 weeks
Significant weight change (>3 kg) within 3 months
Uncontrolled systemic disease (diabetes, hypertension, etc.)
Known hypersensitivity to hyaluronan